

News Release Dated November 7, 2011

Company: tella, Inc.
Representative: Yuichiro Yazaki, Representative
Director and President
Stock code: 2191, Osaka Securities Exchange (JASDAQ)
Contact: Ryohei Yamamoto, Director and
General Manager, Administrative
Headquarters
Tel: +81-3-6272-6477

**Collaborative Clinical Study for Advanced and Recurrent Esophageal Cancer Starts
with Keio University School of Medicine**

Phase 1 clinical study on WT1 peptide pulsed DC vaccine therapy in combination with anticancer drugs

tella, Inc. (Head office: Chiyoda-ku, Tokyo; Representative Director and President: Yuichiro Yazaki) has signed a collaborative research agreement with the School of Medicine of Keio University, which is located in Shinjuku-ku, Tokyo.

Based on this agreement, tella and Keio University will start Phase 1 clinical study for the treatment of advanced and recurrent esophageal cancer in order to evaluate safety of WT1 peptide*¹ pulsed DC (dendritic cell) vaccine therapy*² in combination with anticancer drugs.

1. Background

Esophageal cancer can metastasize easily to lymph nodes and other organs at an early stage of the disease because the esophagus is near so many blood vessels and lymph vessels. As a result, this is one of the most dangerous types of gastroenterological cancers. Currently, standard care such as surgery, chemical therapy and radiation therapy are used to treat this cancer. For advanced and recurrent esophageal cancer, though, treatment of the entire body is needed because the cancer can spread to areas far from the esophagus. Since continuous treatment is not possible for some patients, a new treatment method must be developed in order to improve the prognosis for these individuals. DC vaccine therapy, which is one type of immunotherapy for the treatment of cancer, attacks only cancer cells. Since this property may lead to an effective treatment for metastasizing cancer, there are hopes that DC vaccine therapy can be used as a new treatment for improving the prognosis for individuals suffering from esophageal cancer.

2. Summary of the clinical study

The lead physician for the collaborative clinical study will be Professor Yuko Kitagawa of Department of Surgery, Keio University School of Medicine, who will supervise and conduct the study. Immunological analysis will be performed by Professor Yutaka Kawakami of Division of Cellular Signaling Institute for Advanced Medical Research Keio University School of Medicine. Preparation and administration of DC vaccine will be performed with the cooperation of Tokyo Midtown Medical Center *³, which is one of tella's contracted medical institutions.

tella has the exclusive right to use DC vaccine therapy with WT1 peptides. The Company also has

technologies, know-how and a variety of basic data concerning this therapy. All of these resources will be provided by tella for this collaborative clinical study.

The Company and the Keio University School of Medicine will use this collaborative clinical study to accumulate data based on the scientific evidence for the DC vaccine therapy. The purpose is to evaluate the safety of the treatment.

*1 WT1 peptides

WT1 peptides are a type of protein called WT1 that were discovered by Professor Haruo Sugiyama of Osaka University. Almost all types of cancer (including blood cancer) incorporate WT1. The properties of WT1 can be utilized to permit the use of WT1 peptides, which are part of WT1, for DC vaccine therapy and other therapies. U.S. academic publications have reported that WT1 is the most effective of the new cancer antigens.

*2 DC vaccine therapy

DC (dendritic cell) vaccine therapy is a new type of cancer immunotherapy. This therapy involves the production outside the patient's body of a large volume of monocytes (A special type of cell that is a key regulator of the immune system and capable of activating lymphocytes that defend the body from foreign substances), which normally exist in only small quantities in the blood. These cells are then processed so that they recognize the patient's cancer cells and a compound (new cancer antigens) produced artificially as a tumor marker. Next, the cells are returned to the patient's body so that the characteristics of the cancer are transferred from the dendritic cells to lymphocytes. The lymphocytes can then attack only the cancer cells.

*3 Tokyo Midtown Medical Center

Established in February 2010, this institute provides DC vaccine therapy and other cancer therapies, performs apheresis (a blood cleansing therapy), and performs medical check-ups and outpatient surgical procedures.

Address: Midtown Tower 6F, 9-7-1, Akasaka, Minato-ku, Tokyo 107-6206

Tel: +81-3-5413-7920

Director: Junichi Taguchi